RxDoctor Payments Data

Katherine Hueftle, PA

Physician Assistant · Lexington, NENPI 1649603051

Payments from drug & device makers

$722in general payments, 2019–2025

Across 33 payments — averaging $21.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$226
  • AbbVie$89
  • Lilly USA, LLC$80
  • Kerecis Limited$47
  • Astellas Pharma US Inc$39
  • Alkermes, Inc.$32
  • plus $209 from 11 others

What the payments were for

  • Food & beverage$722100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$722 in reported general payments places this provider in the 65th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$3,192
Medicare patients
26
Services billed
49

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide25$24,480
OzempicSemaglutide20$23,600
XareltoRivaroxaban16$13,156
MounjaroTirzepatide11$9,988
JanuviaSitagliptin Phosphate13$6,612
EliquisApixaban11$6,359
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$5,983
Incruse ElliptaUmeclidinium Bromide11$3,655
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate16$2,779
Ventolin HfaAlbuterol Sulfate26$1,538
Boostrix TdapDiphth,pertuss(Acell),tet Vac18$1,255
Atorvastatin Calcium64$1,107
Omeprazole66$842
Gabapentin59$721
Lisinopril55$710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$80$34,46836 claims
Novo NordiskOzempic$26$23,60020 claims
Johnson & JohnsonXarelto$14$13,15616 claims
MerckJanuvia$15$6,61213 claims
PfizerEliquis$13$6,35911 claims
GSKIncruse Ellipta$13$3,65511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Lexington

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →